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Patients with type 2 diabetes have a several-fold increased risk of developing cardiovascular disease when
compared with nondiabetic controls. Myocardial infarction and stroke are responsible for 75% of all death in
patients with diabetes, who present a 2-4× increased incidence of death from coronary artery disease. Patients with
diabetes are considered for cardiovascular disease secondary prevention because their risk level is similar to that
reported in patients without diabetes who have already suffered a myocardial infarction. More recently, with a
better risk factors control, mainly in intensive LDL cholesterol targets with statins, a significant decrease in acute
cardiovascular events was observed in population with diabetes. Together with other major risk factors, type 2
diabetes must be considered as an important cause of cardiovascular disease.
Glucagon like peptide-1 receptor agonists represent a novel class of anti-hyperglycemic agents that have a
cardiac-friendly profile, preserve neuronal cells and inhibit neuronal degeneration, an anti-inflammatory effect in
liver protecting it against steatosis, increase insulin sensitivity, promote weight loss, and increase satiety or anorexia.
This review is intended to rationally compile the multifactorial cardiovascular effects of glucagon-like peptide-1
receptor agonists available for the treatment of patients with type 2 diabetes.Introduction
When compared with nondiabetic controls, T2D patients
have a several-fold increased risk of developing cardiovascu-
lar disease (CVD) [1]. At least, 68% of people >65 years of
age with diabetes die of some form of CVD. Among adults
with diabetes, CVD death rates are 2-4× higher than the
rates for adults without diabetes [2]. Patients with T2D are
considered for CVD secondary prevention because their risk
level is similar to that reported in nondiabetic patients who
have already suffered a MI [3]. More recently, with a better
risk factors control, mainly in intensive LDL cholesterol tar-
gets with statins, a significant decrease in acute cardiovascu-
lar events was observed in diabetic population. Together
with other major risk factors, T2D must be considered as an
important cause of CVD. Indeed, from a cardiological point
of view, “diabetes is a cardiovascular disease” [4]. Unfortu-
nately, despite significant advances in anti-glycemic therap-
ies, macrovascular complications are still the most common
cause of death in T2D patients [5].* Correspondence: andreisposito@gmail.com
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article, unless otherwise stated.The observation that intrajejunal glucose promotes greater
insulin release than intravenous glucose administration
was reported 50 years ago by McIntyre et al. [6] Perley
and Kipnis estimated the intestinal component accounts
for 50%–70% of the total insulin secreted after an oral
glucose load. The ‘incretin effect’ was coined by Creuzfeld
and Ebert in 1985 to designate this phenomenon [7]. Nauck
et al. [8] demonstrated that the incretin effect is impaired
in patients with T2D. Recently, An et al. observed that the
improvement in the glycemic control potentiates insulin
secretion induced by oral glucose ingestion but does not
change the insulin secretion after iv glucose infusion indir-
ectly demonstrating that the incretin effect is dependent
of glucose/food absorption by the intestines [9].
Glucagon-like peptide 1 (GLP-1) and glucose-dependent
insulinotropic polypeptide (GIP) are the two factors that ac-
count for most of the incretin effect [10]. GLP-1 and GIP
are both secreted in response to food ingestion. GLP-1 is
mainly produced in the enteroendocrine L cells located
in the distal intestine exerting its effects through binding
to the GLP-1 receptors (GLP-1R) expressed in the pan-
creas, heart, blood vessels, gastrointestinal tract (GIT),
kidney, lung, breast, and central nervous system [11,12].
In the pancreatic ß-cell GLP-1, on elevated glucoseCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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(Figure 1) [13].
Because the majority of the α-cells do not express
GLP-1R, and also because GLP-1 inhibits glucagon se-
cretion even in T1D patients with low insulin pancreatic
reserve, the mechanism by which GLP-1 decreases glu-
cagon secretion is still a matter of debate [15]. Recently,
De Marinis et al. reported that GLP-1-induced suppres-
sion of glucagon release is dependent of protein kinase
A (PKA) and independent of glucose or paracrine effects
mediated by insulin or by somatostatin acting on somato-
statin receptor subtype-2 [16,17].
Furthermore, GLP-1 decreases gastrointestinal motility
extending the entry of nutrients to be absorbed by the
GIT [18]. This effect seems to be very important for the
normalization of postprandial glucose (PPG) elevations,
and potentially even more important than the insulino-
tropic effects of GLP-1 for maintaining PPG homeostasis
[19]. Many reports showed that GLP-1 effects involve
neural modulation and peripheral effects, which increaseFigure 1 GLP-1 is released from the small intestine after meal ingestion
DPP-4 rapidly converts GLP-1 and GIP to their inactive metabolites in vivo.
thereby enhancing incretin action (Adapted from Abrahamson MJ. The inc
Mechanisms and Risk Reduction. http://www.medscape.org/viewarticle/557satiety, resting energy expenditure and lower plasma
concentrations of free fatty acids [20-22].
Either GLP-1 or GIP potentiates glucose-dependent
insulin response protecting β-cells against cytokine-
induced apoptosis or glucose [23]. All of these GLP-1 ef-
fects (Figure 2) are potentially beneficial for patients
with T2D, and have been sought exploited clinically with
the development of GLP-1R agonists.
The phenomenon of induction of glucose sensitivity
observed in glucose-resistant ß-cells is called glucose
competence, i.e. the magnitude of the insulin secretion
response to a rise in glucose concentration. More re-
cently, Cornu et al. demonstrated in KO mice that the
regulation of ß-cell number and function by GLP-1 de-
pends on the cAMP/PKA mediated-induction of insulin-
like growth factor-1 receptor (IGF-1R) expression and
the increased activity of insulin-like growth factor 2
(IGF-2)/IGF-1R by an autocrine mode of action [25].
As depicted in Figure 1, dipeptidylpeptidase-4 (DPP-4)
is an ubiquitously expressed transmembrane protein thatand enhance glucose-stimulated insulin secretion (incretin action).
Inhibition of DPP-4 activity prevents GLP-1 and GIP degradation,
reting effect of GLP-1. Diabetes, Cardiovascular Disease and Stroke:
239 and reference [14]).
Figure 2 Pleitropic effects of GLP-1 or GLP-1R agonists (Adapted from references [24]).
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hormones, chemokines, neuropeptides and growth fac-
tors. DPP-4 inhibitors (DPP-4i) block degradation of
GLP-1 and GIP, extend their insulinotropic effect, and
improve glycemia [26].
Although the SAVOR and EXAMINE studies were de-
lineated to verify cardiovascular safety of two DPP-4i,
namely saxagliptin and alogliptin, respectively, both are
considered to be the first controlled clinical trials to ad-
dress the effect of GLP-1 system on CVD. In the SAVOR
study DPP-4 inhibition with saxagliptin did not increase
or decrease the rate of ischemic events, though the rate
of hospitalization for heart failure was increased [27].
On the other hand, EXAMINE study showed that T2D
patients, who had had a recent acute coronary syn-
drome, the rates of major adverse cardiovascular events
were not increased with the DPP-4 inhibitor alogliptin
as compared with placebo [28].
GLP-1R agonists represents a novel class of anti-
hyperglycemic agent that improve health and survival of
ß-cells (improvement in postprandial hyperglycemia), sup-
press glucagon (improvement in fasting hyperglycemia),improve insulin resistance (modest effect) and influence
energy intake (augment satiety signal) with minimal, if at
all, any side effects (weight neutral and non-hypoglycemic).
The incretins address most of the proposed pathophysio-
logic mechanisms involved in the development of T2D
(Figure 2). Besides the ß-cell dysfunction, incretin defi-
ciency is now considered among the key factors in the
pathophysiology of T2D. So, exogenous GLP-1R agonists
have been more recently considered as a good choice for
treating patients with diabetes [29].
In this brief review, we shall discuss recent important
evidences of the potential clinical benefit of the incretin
effect on cardiovascular system as well as the biological
mechanisms, which underlie these effects.GLP-1R distribution in the cardiovascular system
GLP-1R is a member of the class B1 family of G protein-
coupled receptor for which there are only predicted
structures [30]. GLP-1R has been detected by reverse
transcriptase-polymerase chain reaction in cardiac and
vascular tissues isolated from both human and animal
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onstrated in the human heart [32].
GLP-1R protein has also been detected in human
coronary artery endothelial cells (HCAEC) and human
umbilical vein endothelial cells (HUVEC) [33,34]. Ban
et al. detected GLP-1R protein expression by immuno-
histochemistry in mouse coronary endothelial and
smooth muscle cells [35].
Many reports using polyclonal antisera were unable
to detect GLP-1R protein in ventricular cardiomyocytes
leaded to the revaluation of those earlier reports. Be-
cause of lack of sensitivity and problems with non-
specificity of commercially available GLP-1R antisera
detected multiple nonspecific immunoreactive proteins
even in tissue extracts from Glp1r−/− mice. Although
Glp1r mRNA transcripts are detected in whole heart
extracts such methods do not distinguish between
vascular smooth muscle cells or atrial cardiomyocytes,
there were technical difficulties in isolating pure cardio-
myocyte populations from the ventricle without contam-
ination of atrial cardiomyocytes isolated from neonatal
mouse [36].
Cardiac GLP-1R signaling pathways
There is considerable overlap between pathways induced
by the GLP-1R activation. As shown in Figure 3, GLP-1R
couples to adenylyl cyclase leading to the activation of
cAMP. Using a GLP-1 conjugated to tetramethyl rhoda-
mine to monitor the internalization of the receptor, KunaFigure 3 Intracellular signaling pathways of GLP-1R in the cardiomyoet al. [37] observed that after internalization, GLP-1R/ligand
complex could be co-localized with adenylate cyclase
in the endosome. Indeed, cAMP levels can be elicited
by GLP-1 treatment of mouse cardiomyocytes without
increasing intracellular Ca2+ or inducing contractility [38].
The involvement of cAMP/PKA/CREB pathway on de-
crease myocyte apoptosis has been unveiled by experi-
ments prepared in cultured mouse cardiomyocytes. This
function is mediated via the activation of the cAMP/PKA/
CREB (cAMP-responsive element binding protein) and
the transactivation of the EGF-R (epidermal growth factor
receptor) leading to the activation of phosphatidylinositol-
3 kinase (PI3K), protein kinase Cζ(PKCζ), Akt-protein kin-
ase B (AKT/PKB), extracellular regulated kinase (ERK1/2
or mitogen-activated protein kinase [MAPK]) signaling
pathways and to the up-regulation of the expression of the
cell cycle regulator cyclinD1 (Figure 3). The increase in
Akt and ERK phosphorylations lead to cardiomyocyte
growth and activation of glucose metabolism [24,39-41].
The main mechanism of cardioprotective effects of
GLP-1R agonists against oxidative stress-induced injury
in H9c2 cells (cardiomyoblasts from Rattus norvegicus)
and in cardiomyocytes is related to the scavenging of re-
active oxygen species, by increasing the concentrations
of endogenous antioxidant defenses and inhibiting car-
diomyocyte apoptosis [42]. This cytoprotective effect is
mediated by PI3K and partially dependent on ERK1/2
and seems to be glucose-independent. A protective role of
retinoid X receptor is also related to hypoxia/reoxygenationcytes (Adapted from references [36,39]).
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palmitate- and ceramide-induced phosphatidylserine expos-
ure and DNA fragmentation [44].
Effects of GLP-1R activation in the heart
The observation that GLP-1 decreases contractility in pri-
mary culture of adult rat cardiomyocytes, despite increas-
ing cAMP levels, [38] has also been reported in isolated
rat hearts [45]. Studies in dogs demonstrated an increased
myocardial glucose uptake during a hyperinsulinemic-
euglycemic clamp [46].
Moreover, cardiometabolic effects of GLP-1 are attenu-
ated in obesity and T2D, via mechanisms that may involve
impaired p38-MAPK signaling. Using a swine experimen-
tal model, Moberly et al. confirmed and extended the ob-
servation, where GLP-1 significantly increased myocardial
glucose uptake under basal conditions in lean humans,
but this effect was impaired in T2D [47]. GLP-1 did not
increase myocardial oxygen consumption or blood flow in
humans or in swine, increasing p38-MAPK activity in
lean, but not obese cardiac tissue [48].
Experimental studies in animals suggested that incre-
tins may preserve cardiomyocyte viability, increase meta-
bolic efficiency, inhibit the structural, and functional
remodeling after MI [49]. Shannon’s group was the first
to demonstrate that infusion of GLP-1(7-36) (1.5 pmol/
kg/min) for 72 h in patients with left ventricular dys-
function (LVD) after MI improved global and regional
left ventricular wall motion scores reducing hospital stay
and in-hospital mortality [50,51].
GLP-1-mediated control of heart rate (HR) and blood
pressure (BP) is complex and species specific. Synthetic
human GLP-1 administered into the jugular vein of male
rats acutely increased systolic and diastolic BP, as well as
HR, which returned to basal levels 25 min after GLP-1
administration. The pre-treatment with propranolol or
phentolamine did not prevent the increase in BP and
HR. In rodents, these increases involve a dual pathways
originating from both central nervous system and per-
iphery with intact neural vagus transmission [52].
Intravenous infusion of GLP-1 for 48 h in healthy hu-
man subjects increased muscle sympathetic nerve activity
but had no effect on BP, norepinephrine plasma concen-
tration, or the sympathetic/parasympathetic balance as es-
timated by the HR variability, suggesting that the increase
in sympathetic drive is at least partially compensated by
an increase in the parasympathetic activity [53]. On the
other hand, acute subcutaneous (SC) injection of GLP-1
increases HR and BP transiently in healthy human sub-
jects, returning to normal ranges 50-60 min after injection
[54]. A mean increase in HR of 1.86 beats/min was re-
ported in a meta-analysis including available data from
randomized controlled trials testing GLP-1 agonists against
placebo in patients with T2D [53].In the cardiovascular system, incretins have been recently
associated to the increase of endogenous antioxidant de-
fenses, inhibition of cardiomyocyte apoptosis, attenuation
of endothelial inflammation and dysfunction [55].
GLP-1R activation and artery wall function
GLP-1 has pleiotropic effects on the cardiovascular sys-
tem. A GLP-1R agonist (liraglutide) increased endothelial
nitric oxide synthase phosphorylation and nitric oxide
(NO) production by the 5-AMP-activated protein kinase
(AMPK)-dependent pathway and subsequent NO produc-
tion in cultured HCAEC [56,57]. GLP-1 protects the car-
diac microvessels against oxidative stress, apoptosis, and
the resultant microvascular barrier dysfunction in dia-
betes, contributing to improvement of cardiac function
and cardiac glucose metabolism. The protective effects of
GLP-1 are dependent on downstream inhibition of Rho
through a cAMP/PKA-mediated pathway [58].
As shown by Batchuluun at al., metformin and liraglu-
tide improve high glucose-induced oxidative stress via
inhibition of PKC-NADPH oxidase pathway in human
aortic endothelial cells. All these effects were even more
pronounced when both drugs were used together, sug-
gesting a potential clinical benefit of this drug combin-
ation in decreasing the endothelial damage induced by
hyperglycemia [59].
In humans, Kelly et al. showed that exenatide therapy
for that 3-mo in patients with obesity and pre-diabetes
had similar effects on microvascular endothelial function,
markers of inflammation, oxidative stress, and vascular ac-
tivation, as metformin. They assumed that improvements
in endothelial function with GLP-1R agonists might be
limited to the postprandial setting, particularly following
the consumption of a high-fat meal [60].
GLP-1 enhanced acetylcholine-induced forearm blood
flow but had no effect on blood flow induced by sodium
nitro-prusside in healthy human subjects [61]. Patients
with T2D with stable CAD presented an improvement
in endothelial function expressed by an increase in flow-
mediated vasodilation of the brachial artery, independent
of changes in systolic and diastolic blood pressure dur-
ing a hyperinsulinemic clamp in response to GLP-1 [35].
However, GLP- 1-mediated improvements in blood flow
were considerably attenuated after a 2-month period of
better glycemic control [62].
In obese patients, GLP-1 infusion significantly increased
excretion of sodium (by 60%), calcium (by 60%) and chlor-
ide (by 44%) and significantly decreased excretion of H+
(by 75%). Besides these renoprotective qualities, these
changes suggest that GLP-1 may have renoprotective qual-
ities [63]. Moreover, Kim et al. demonstrated that cardiac
GLP-1R expression is localized in cardiac atria and that
GLP-1R activation promotes secretion of atrial natriuretic
peptide (ANP) and increases BP [64].
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impact the development and/or progression of athero-
sclerotic plaques. Since GLP-1R has been localized by
immunocytochemistry in mouse aortic smooth muscle
cells, endothelial cells, monocytes, and macrophages,
both direct and indirect actions of GLP-1 may contrib-
ute to the potential reduction of atherogenesis. Continu-
ous infusion of exendin-4 in nondiabetic C57BL/6 and
ApoE−/− mice reduced monocyte adhesion to aortic
endothelial cells and atherosclerotic lesion size after
40 days of treatment. The inflammatory markers mono-
cyte chemoattractant protein-1 (MCP-1) and tumor ne-
crosis factor α (TNF-α), were reduced by treatment with
exendin-4 in response to lipopolysaccharide in cultured
peritoneal macrophages harvested from mice [65]. How-
ever, circulating GLP-1 was found to be positively asso-
ciated with total coronary load in humans in a fully
adjusted model [OR: 2.53 (95% CI: 1.12-6.08; p = 0.03)],
[66] but further studies are required to confirm these
observations.
Continuous infusion of exendin-4 for 4 wk. in C57BL/
6 mice reduced neointimal formation after endothelial
denudation of the femoral artery [67]. Nagashima et al.
[68] reported that continuous GLP-1 infusion reduced
foam cell formation and the development of atheroscler-
otic lesions in ApoE−/− mice. Recently, the same group
demonstrated similar effects after infusion of liraglutide
in apoE−/− mice [69]. In addition to these findings on
atherosclerotic plaque formation, GLP-1R agonists pre-
vented the increase in plasminogen activator inhibitor
type-1 (PAI-1) and vascular cell adhesion molecule-1
(VCAM-1) gene expression in response to TNF-α or
hyperglycemia in HUVEC through PKA pathway [24,70].
GLP-1R agonists effects on cardiovascular events
The first pieces of evidence of the potential clinical
benefit of GLP-1 agonists have emerged recently, point-
ing to a decrease of major adverse cardiovascular and
cerebrovascular events (MACCE) including stroke, MI,
cardiac mortality, acute coronary syndrome, and revas-
cularization procedures. A retrospective medical database
analysis of T2D patients (n = 39,275) treated with exena-
tide or other glucose-lowering therapies (n = 381,218) in-
dicated that the GLP-1 agonist might reduce in 19% the
incidence of MACCE and in 12% cardiovascular hospitali-
zations [71]. Despite the absence of adverse cardiovascular
effects has been confirmed, this benefit was not verified in
an integrated analysis of 12 controlled, randomized, short-
term clinical trials (12-52 weeks) comparing exenatide
with placebo or insulin [72].
In both diabetic and non-diabetic patients presenting
class II/IV heart failure, GLP-1 infusion led to an im-
provement of left ventricular (LV) ejection fraction,
myocardial ventilation oxygen consumption, 6-min walkdistance, and quality of life [50]. A study with infusion
of exenatide in T2D patients with chronic heart failure
reduced the pulmonary capillary wedge pressure and in-
creased both inotropism and chronotropism [73]. These
favorable results require further clinical trials in order to
elucidate whether these effects will result or not in re-
duced mortality. In a study involving patients with CAD
and preserved LV function, who were scheduled to
undergo coronary artery bypass grafting (CABG), were
randomized to receive standard therapy or treatment
with GLP-1 (1.5 pmol/kg/min) as a continuous infusion
beginning 12 h before CABG and continuing for 48 h
after the procedure. The control group required greater
use of inotropic and vasoactive infusions during the 48 h
period after CABG to achieve the same hemodynamic
results observed in the group receiving GLP-1. There
were also more frequent arrhythmias requiring anti-
arrhythmic agents in the control group [50].
In a non-randomized pilot study, Nikolaidis et al. in-
vestigated the safety and efficacy of a 72-h infusion of
native GLP-1 combined to background therapy in 10 pa-
tients with acute MI and LV ejection fraction <40%
(mean 29 ± 2%) after successful primary angioplasty,
compared to 11 control patients. GLP-1 treatment was
safe and elicited a significant improvement in LV ejec-
tion fraction (to a mean of 39 ± 2%) [74].
In a study involving 14 patients with normal ejection
fraction and CAD awaiting revascularization, normal
saline and native GLP-1 were infused on two different
occasions from 30 min before until 30 min after a dobuta-
mine stress echocardiography for evaluation of the global
LV function; native GLP-1 significantly improved LV func-
tion at peak stress and at 30 min into recovery, predomin-
antly in ischemic segments [75].
Fifty-eight patients with ST-segment-elevation MI and
thrombolysis were randomized to receive either saline
(n = 40) or exenatide (n = 18, 10 μg SC and 10 μg as an
IV bolus 5 min before the onset of reperfusion plus
10 μg SC twice daily on the following 2 days) to evaluate
whether this GLP-1R agonist could reduce the area
of necrosis; exenatide administration significantly de-
creased release of CK-MB and troponin and reduced
infarct size as evaluated by cardiac magnetic resonance
after 1 month [14].
Differences between GLP-1R agonists
GLP-1R agonists already in the market and others in de-
velopment present the same mode of action and, having
the same pleiotropic effects of native GLP-1, the differ-
ences in clinical profiles between them are related to dif-
ferences in pharmacokinetics, structure and size of each
formulation. The most remarkable clinically Important
pharmacokinetic characteristic is the difference between
the short-acting and continuous-acting compounds
Table 1 Effects of the short- and continuous-acting








GLP-1R activation Intermittent Continuous
HbA1c reduction + ++
FPG reduction + ++
PPG reduction ++ +
Gastric emptying deceleration ++ ←→
Body weight reduction ++ ++
Blood pressure reduction + +
Hearth rate increase ←→ +
Abbreviations: GLP-1R glucagon-like peptide-1 receptor, HbA1c glycated
haemoglobin, FPG fasting plasma glucose, PPG postprandial glucose.
*Exenatide once-weekly.
Table 2 Compilation of the most important results of GLP-1 a
the text
GLP-1 Referen
Elicits cAMP in mouse cardiomyocytes [38]
Inhibits palmitate- and ceramide-induced
phosphatidylserine exposure and DNA fragmentation
[44]
Increases myocardial glucose uptake in dogs [46]
May preserve cardiomyocyte viability, increases
metabolic efficiency and inhibits the structural and




Increases systolic and diatolic BP, as well as HR
im male rats acutely.
[52]
Inhibts glucagon release by a mechanism PKA
dependent and glucose independent
[16,17]
Decreases contractility in primary culture of adult rat
cardiomyocytes and in isolated rat hearts
[45,76]
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once weekly elicited a greater response than did short-
acting exenatide, improving glycemic and lipids con-
trols and lipoprotein metabolism, and decreasing sys-
temic inflammation. Indeed, as shown by Hermansen
et al. liraglutide treatment in patients with T2D signifi-
cantly reduced postprandial excursions of triglyceride and
apo B48 after a fat-rich meal, independently of gastric
emptying. Results indicate that liraglutide’s potential to re-
duce CVD risk via improvement of postprandial lipemia.
Meloni et al. calculated the absolute benefit increase
of using exenatide once week, GLP-1R agonist, vs an
oral glucose-lowering medication or insulin glargina to
achieve ADA-recommended goals. Exenatide once a
week assisted more patients in reaching the majority of
ADA-recommended therapeutic goals than treatment
with sitagliptin, pioglitazone, or insulin glargine.Conclusions
Mechanistic and preliminary clinical evidence have con-
sistently pointed toward beneficial effects of GLP-1 ana-
logues and GLP-1R agonists on cardiovascular diseases
in T2D patients. Indeed, a search at http://www.clinical-
trials.gov (as of, Sep ’14), employing cardiovascular dis-
ease and GLP-1 as keywords, returns 112 recordsnd GLP-1R agonists from animal studies mentioned in
ces GLP-1R agonist References
mRNA
Expression is localized in cardiac atria and and its
activation promotes secretion of atrial natriuretic
peptide and increases BP.
[11,31,64]
Acts via cAMP in endosome [37]
Decreases myocyte apoptosis by activation of
cAMP/PKA/CREB pathway
[39]
Induces cardiomyocyte growth and activation of
glucose metabolism by a mechanism envolving AKT
and ERK phosphorylations
[24,40,41]
Has cardioprotective functions related to inhibition of
cardiomyocytes apoptosis due their ROS scanvenger
actions, by increasing endogenous antioxidant
defenses.
[42]
Cardioprotective functions are mediated by PI3K and
partially dependent on ERK1/2
[43]
Attenuates atherosclerotic lesions by reducing
monocyte/macrophage accumulation in the arterial
wall and inhibits the inflammatory response in
macrophages.
[65]
Reduces the inflammatory markers: MCP-1 and TNF-α
in response to lipopolysaccharide in cultured peritoneal
macrophages harvested from mice.
[66]
Reduces monocyte adhesion to aortic endothelial
cells and atheroscleroticlesion size in nondiabetic
C57BL/6 and ApoE−/− mice.
[65]
Table 3 Compilation of the most important results of GLP-1 and GLP-1R agonists from human studies mentioned in
the text
GLP-1 References GLP-1R agonist References
Decreases gastrointestinal motility extending
the entry of nutrients to be absorbed by the GIT
[18] mRNA transcripts were demonstrated
in the human heart.
[31]
Normalizes postprandial glucose elevations by
decreasing TGI motility, which seems to be more
important than its insulinotropic effects.
[19] Induces a mean increase in HR
in patients with T2D.
[77]
Improves endothelial function expressed by an
increase in flow-mediated vasodilation of the
brachial artery, independent of changes in
systolic and diastolic blood pressure during
a hyperinsulinemic clamp in patients with
T2D with stable CAD.
[36] Increases endothelial nitric oxide synthase
phosphorylation and nitric oxide production
by the AMPK-dependent pathway in cultured
Human Coronary Artery Endothelial Cells.
[56,57]
Increases myocardial glucose uptake under basal
conditions in lean humans, but this effect was
impaired in T2D.
[47] With metformin ameliorates high glucose-induced
oxidative stress via inhibition of PKC-NAD(P)H
oxidase pathway in human aortic endothelial cells.
[59]
improves global and regional LV wall
motion scores reducing stay and in-hospital
mortality of patients with LV dysfunction
after myocardial infarction.
[50,51] Increases endogenous antioxidant defenses,
inhibits of cardiomyocyte apoptosis, attenuates of
endothelial inflammation and dysfunction.
[62]
Protects against cardiac microvascular
injury in diabetes via a cAMP/PKA/
Rho-dependent mechanism.
[58] Reduces in 19% the incidence of major adverse
cardiovascular and cerebrovascular events (MACCE)




[61] Reduces pulmonary capillary wedge pressure and
increased both inotropism and chronotropism. In




Increases muscle sympathetic nerve activity
without affecting BP, norepinephrine plasma
concentration, or the sympathetic/parasympathetic
balance, where sympathetic drive is at least partially
compensated by an increase in the parasympathetic
activity
[62] Reductes infarct size and improves subclinical LV
function when added to primary percutaneous
coronary intervention in patients with ST-segment-
elevation myocardial infarction.
[14]
May have renoprotective function by significantly increased
excretion of sodium, calcium, and chloride and significantly
decreased excretion of H + in obese patient.
[63] When administered once in a week assistes more
patients in reaching the majority of ADA-
recommended therapeutic goals than treatment
with sitagliptin, pioglitazone, or insulin glargine as
shown by clinical trials.
Concentration in human plasma is found to be positively
associated with total coronary plaque load.
[66] When administered once in a week elicites a greater
response than does short-acting
exenatide once a day, improving glycemic and
lipids controls, lipoprotein metabolism, and
decreasing systemic inflammation.
Improves LVEF, myocardial ventilation oxygen consumption,
6-min walk distance, and quality of life. In both diabetic and
non-diabetic patients presenting class II/IV heart failure
[78]
Achieves better glycemic control and comparable
hemodynamic recovery without the requirements for high-
dose insulin or inotropes when infused perioperatively in
patients with CAD and preserved LV function scheduled to
undergo coronary artery bypass grafting. There were also
more frequent arrhythmias requiring anti-arrhythmic agents
in the control group.
[79]
Treatment is safe and elicites a significant improvement
LVEF in patients with acute MI and LVEF <40% after
successful primary angioplasty when compared with
control.
[74]
Protects the heart from ischemic LV dysfunction induced by
dobutamine stress in patients with CAD.
[75]
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recruiting, 6% active, but not yet recruiting, 4% termi-
nated, and 1% withdraw studies. Among those, 12%
studies has results and 88% has no results available,
which indicates towards an increasing interest in the
cardiovascular effects of incretin-based therapies. The
actual evaluation of cardiovascular benefits will be
achieved with the completion of the Liraglutide Effect
and Action in Diabetes: Evaluation of Cardiovascular
Outcome Results (LEADER) trial, which enrolled 9,340
T2D patients randomized for treatment with liraglutide
or placebo for an estimated period of 5 years (Clinical-
Trials.gov Identifier: NCT01179048).
Tables 2 and 3 depict the most important results of
GLP-1 and GLP-1R agonists from animal and human
studies mentioned in the text.
The potential cardiovascular benefits expected from
this new therapeutic approach to obtain glycemic con-
trol in T2D arises a possibility to change the excessive
cardiovascular burden related to this disease in both de-
veloped and developing countries worldwide.
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